JPMorgan Chase & Co. Raises Stoke Therapeutics (NASDAQ:STOK) Price Target to $13.00

Stoke Therapeutics (NASDAQ:STOK) had its price objective upped by JPMorgan Chase & Co. from $6.00 to $13.00 in a research report report published on Tuesday morning, Benzinga reports. They currently have a neutral rating on the stock.

STOK has been the topic of a number of other reports. Needham & Company LLC reiterated a buy rating and set a $14.00 target price on shares of Stoke Therapeutics in a report on Friday, February 16th. Canaccord Genuity Group increased their target price on shares of Stoke Therapeutics from $18.00 to $21.00 and gave the stock a buy rating in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of Moderate Buy and an average price target of $19.63.

Stoke Therapeutics Trading Down 4.7 %

Shares of NASDAQ STOK opened at $13.50 on Tuesday. The company has a 50-day moving average of $6.24 and a 200 day moving average of $5.08. Stoke Therapeutics has a 12-month low of $3.35 and a 12-month high of $16.40. The stock has a market cap of $625.05 million, a PE ratio of -5.70 and a beta of 0.68.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, CFO Stephen J. Tulipano sold 4,116 shares of the stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $25,107.60. Following the sale, the chief financial officer now directly owns 20,746 shares of the company’s stock, valued at approximately $126,550.60. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CEO Edward M. Md Kaye sold 11,150 shares of the stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $68,015.00. Following the transaction, the chief executive officer now directly owns 69,350 shares of the company’s stock, valued at approximately $423,035. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Stephen J. Tulipano sold 4,116 shares of the firm’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $25,107.60. Following the transaction, the chief financial officer now directly owns 20,746 shares in the company, valued at $126,550.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 37,615 shares of company stock valued at $212,852. Insiders own 12.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Ensign Peak Advisors Inc acquired a new stake in shares of Stoke Therapeutics in the 1st quarter worth $25,000. Point72 Hong Kong Ltd acquired a new stake in shares of Stoke Therapeutics in the 1st quarter worth $27,000. Great West Life Assurance Co. Can lifted its stake in shares of Stoke Therapeutics by 46.7% in the 1st quarter. Great West Life Assurance Co. Can now owns 3,387 shares of the company’s stock worth $28,000 after acquiring an additional 1,078 shares during the period. Dorsey & Whitney Trust CO LLC acquired a new stake in shares of Stoke Therapeutics in the 3rd quarter worth $43,000. Finally, UBS Group AG acquired a new stake in shares of Stoke Therapeutics in the 3rd quarter worth $47,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.